title: Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
authors.forename: S
authors.initials: S
authors.lastname: Lourari
authors.forename: S
authors.initials: S
authors.lastname: Prey
authors.forename: C
authors.initials: C
authors.lastname: Livideanu
authors.forename: B
authors.initials: B
authors.lastname: Jamard
authors.forename: L
authors.initials: L
authors.lastname: Lamant
authors.forename: A
authors.initials: A
authors.lastname: Cantagrel
authors.forename: C
authors.initials: C
authors.lastname: Paul
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use*; D000069285:Infliximab; D016410:Lymphoma, T-Cell, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012307:Risk Factors; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept